The ALIM drug for the treatment of diabetic macular edema did not recieve an approval from the FDA and both stocks have suffered since that event in December. Still, the stock's have more or less gone sideways over the past few months.
The drug (actually, a drug-delivering device) will again be evaluated by the FDA in mid-November 2011. Things are on hold until then, but ALIM appears to need to raise a bit of additional capital to get a launch underway if it is approved.
This one is only for highly risk-tolerant speculators, as is typical of development-stage drug outfits.
This one has been a bummer!
No comments:
Post a Comment